Summary Specimens from 45 patients with previously-untreated non-small cell lung cancer (NSCLC) were tested for in vitro chemosensitivity to ten drugs utilising the DiSC assay, which measures cell kill in the total (largely non-dividing) tumour cell population. Thirty-five assays were successful and 25 patients with advanced disease subsequently received chemotherapy with the 'best' three drugs selected by the assay. Six patients were Karnofsky performance status 60 or less and the median pretreatment weight loss was 8.5%. Nine patients had a partial response (response rate = 36%; 95% confidence interval = 17-55%) and the median survival of all patients was 202 days. Specimens from responding patients were significantly more sensitive in the assay to drugs in general (especially to etoposide and to 'natural product' drugs) and to the drugs used in treatment than were specimens from non-responding patients. In vitro drug resistance differences between responding and non-responding patients were of greater significance than were differences between other clinical and laboratory measurements. Assay results classified patients into two cohorts, having relatively high and low probabilities of responding to chemotherapy. Assay results also identified patient cohorts with above average and below average durations of survival. Five patients (20%) were found to have tumours with extreme drug resistance (EDR), defined as assay results for the average of all ten tested drugs falling greater than one standard deviation more resistant than the median for all tumours assayed, and none of these patients with EDR responded to chemotherapy.
No single program of chemotherapy has emerged as the standard of treatment for patients with advanced non-small cell lung cancer (NSCLC). Randomised comparisons have covered a ranged of options including multidrug and single drug therapy and no chemotherapy (Mulshine et al., 1986; Hansen, 1987) . Therapeutic choice has often been without significant impact on survival. Where statistically significant survival improvement has been reported the magnitude of the benefit has been modest and caution seems appropriate in weighing this benefit vs the toxicity from the treatment.
One hope for improving treatment outcome has been the provision of customised treatment on the basis of individual tumour properties. From December 1983 through August 1986 we investigated this approach with a pilot study of individualised chemotherapy for NSCLC selected on the basis of an in vitro drug resistance assay. The assay chosen was a dye exclusion assay (the DiSc Assay) which has received extensive study in haematologic neoplasms (Weisenthal et al., 1984; Weisenthal et al., 1986; Bird et al., 1985; Bosanquet et al., 1983; Bird et al., 1986; Tidefelt et al., 1989; Kirkpatrick et al., 1990; Lathan et al., 1990; Bosanquet, 1991) , but more preliminary evaluation in solid tumours Gazdar et al., 1990) .
We are now reporting the final results of this trial.
Methods and materials

Patients
All patients with unresectable NSCLC cared for at the Pettis Memorial Veterans Hospital were potentially eligible if a tumour sample could be obtained without major surgery or incidentally during an otherwise indicated major surgery.
Exclusion criteria were failure to obtain a successful in vitro assay, a Karnofsky performance score <40, a clinical life expectance < 1 month, a serum creatinine > 2, uncompensat- Survival curves were calculated by the product limit method and the BMDP statistical package was used for both single factor survival comparisons and multivariate proportional hazards modeling of the survival distribution (Dixon et al., 1985) . The Fisher exact test was used for comparisons of response and survival proportions (Matthews & Farewell, 1988) . Differences between sample means were compared by T test. Tests were either one-or two-tailed, as noted in the results. Many of our patients were in poor general condition as shown by the fact that 12 of 25 had albumin levels less than 3.5. Six patients had a Karnofsky performance score of 60 or less. The median pretreatment weight loss was 8.5%. Tumour samples came largely from lymph nodes (mediastinal-4, supraclavicular-8, peripheral-3) but came also from the primary (4) and skin/subcutaneous sites (4). The time from collecting the sample for in vitro study to the initiation of chemotherapy was 6 to 439 days but was <32 days in 21 of the 25 patients. In only two cases were results from less than the full panel of nine drugs used.
Early deaths (2 in < 21 days) or failures to return for follow up (1) were considered treatment failures. Table III gives data on response frequency and duration. A 36% objective PR rate was seen with a median survival of 202 days and a median time to progression of 118 days. Although it does not prove a therapeutic benefit, it is of some interest that the responders lived longer than the nonresponders (P = 0.005, one sided). This at least suggests some biologic differences between these sets of patients. A univariate analysis of clinical data at optimally-selected cutpoints revealed a positive correlation of a number of factors with survival, including: WBC less than 9,000 (P = 0.02, two-sided), Karnofsky performance status (KPS) greater than 80 (P = 0.01, one-sided), height/weight squared greater than 22 (P=0.01, one-sided), and weight loss less than 10.1% (P = 0.02, one-sided). Other independent variables not correlated significantly with survival included albumin, LDH, alkaline phosphatase, haemoglobin, and platelet count. Although the 15 patients receiving cisplatin had an insignificantly higher response rate than the patients not receiving cisplatin, survival for the cisplatin-treated patients was shorter (median 141 days for cisplatin-treated patients and 219 days for non-cisplatin-treated patients).
Twenty different drug combinations (of a possible 504) were used, none more than twice. Of a possible 36 pair-wise drug concentrations, 30 were actually used. The small number of patients limited interpretation, but Table IV does provide exploratory response and usage data for single drugs and for pairs appearing three or more times. Lack of response for all eight receiving 5FU is perhaps notable in view of theoretical considerations that total cell kill assays, such as the DiSC assay used in this study, may not provide reliable predictions for 5FU (see Discussion).
No unique toxicities were seen though the usual side effects of these agents were observed including haematologic depression, nausea and anorexia. The most bothersome toxicity was protracted anorexia and malaise in cisplatin treated patients even ones who had no complaints of nausea with treatment. This caused delay or interruption of treatment in almost half the cisplatin treated patients.
Assay/treatment correlations We also looked for correlations between the level of in vitro drug resistance and the clinical outcome of response and survival. For this analysis, we addressed two separate issues. First, did responding and non-responding patients have measurable differences in drug resistance in vitro? Second, at specific assay cut-off points, was in vitro drug resistance predictive of response or survival?
A series of assay parameters was evaluated for differences between reponders and non-responders. With the exception of 5FU, all assay parameters showed a trend for lower assay cell survival (greater cell kill) in responders than in nonresponders. This was significant for the parameters listed in Table V , bit not significant in the case of the 'best' single drug and single drug data for nitrogen mustard, cisplatin, carmustine, lomustine, vinblastine, vincristine, and mitomycin c. A large series of clinical factors was also reviewed to Luedke et al., 1987; Ganz et al., 1989) . We feel that continued innovative trials are much needed. However, in order to demonstrate a 25% improvement in median survival in a randomised trial through assay-directed drug selection, 600 patients would be required (one-sided test, power of 0.8, allowing also for a 20% assay inevaluability rate). Unfortunately, in a recent Eastern Cooperative Group trial to evaluate the DiSC assay in. NSCLC (EST B-585), five patients were accrued in 12 months (LMW, unpublished experience).
Technical and theoretical considerations regarding assay methodology The DiSC Assay, studied here, is quite different from the 'clonogenic' assays more extensively studied by previous investigators (von Hoff et al., 1981; Scheithauer et al., 1988; Salmon, 1987; Hanauske et al., 1987; Hoff, 1986; Link et al., 1986; Sondak et al., 1985) . The endpoint of this assay is cytolysis (direct cell killing which results in loss of membrane integrity), as opposed to inhibition of cell proliferation, which is measured in 'clonogenic' assays. Furthermore, cytolysis in the DiSC Assay is measured in the entire tumour cell population, which consists of largely non-proliferating cells.
The theories behind this assay have been previously considered Weisenthal et al., 1984; Weisenthal & Lippman, 1985; Weisenthal et al., 1986; Weisenthal, 1987; Weisenthal et al., 1988; Weisenthal, 1991 Berger, 1985) . These cellular lesions may be achieved only through the use of relatively high in vitro drug concentrations. Yet the mechanisms protecting the reproductive integrity of the cell at low (clinical) drug concentrations (e.g. diminished drug transport, enhanced drug export, altered topoisomerase activity, and increased repair efficiency) may be similar and proportional to the mechanisms protecting the cytologic integrity at high (in vitro) drug concentrations. Thus, if one calibrates the assay at a certain drug concentration and assay duration, then testing a variety of tumours under the same conditions can plausibly discriminate between cell populations with differing in vitro levels of resistance which reflect differing clinical levels of resistance.
On the other hand, with other drugs in vitro resistance may not parallel clinical resistance. For example, if the most important clinical effect of 5FU is the inhibition of cell division through the inhibition of thymidylate synthetase, then measuring cytolysis in non-dividing cells in vitro (e.g. mediated through incorporation of 5FU into 'fraudulent' RNA) may not give assay results correlating with clinical drug resistance. These theoretical considerations also apply to other assay systems measuring cell damage in the total (largely non-dividing) tumour cell population (e.g. (Rotman et al., 1988; Campling et al., 1988) ). In our present study, it was striking that none of the eight patients assigned to receive chemotherapy which included 5FU responded. Certainly, we would not, in future trials, include 5FU as a drug to be selected by the results of any in vitro assay which measures cell damage in the total tumour cell population.
At the concentrations tested in the assay, nitrogen mustard was, on the average, the most active agent and was significantly more active than were several other drugs, such as etoposide. This probably does not reflect the clinical situation and most likely resulted from testing a disproportionately high concentration of nitrogen mustard in vitro, relative to the concentrations of the other agents tested.
The above considerations point out the difficulty of comparing the results of (for example) 5FU treatment and drug resistance assay in one patient with etoposide treatment and assay in another patient. Firstly, the assay may be valid for etoposide and not valid for 5FU and, therefore, a 20% cell survival assay result for etoposide in patient A would not likely be comparable to a 20% cell survival assay result for 5FU in patient B. Secondly, the assay could be individually valid for both drugs, but the drug concentrations tested might not be calibrated precisely enough to allow direct U) l comparison between percent cell survivals in vitro (e.g. 50% cell survival in vitro might indicate drug sensitivity at the concentration tested for etoposide, while 20% cell survival in vitro might be required to indicate drug sensitivity at the concentration tested for nitrogen mustard). However, comparisons of the same drug at the same concentration in different patients may be more valid (e.g. 50% cell survival to etoposde in patient A might indicate greater drug sensitivity to etoposide than 100% cell survival to etoposide in patient B). These latter considerations point out a weakness in the present study, where drugs were selected on the basis of the lowest absolute cell survival, rather than on the basis of a calibrated, 'normalised' value (e.g. deviation from the median result of all assays with a given drug, see below), which could, on the basis of the data obtained in the present study, now be calculated for subsequent assays.
Predictive accuracy of assay All cell culture assays are, for biological and statistical reasons, much better at detecting drug resistance than drug sensitivity (Weisenthal, 1991) . For this reason, it is perhaps unfair to assess the predictive accuracy of a particular assay system in a study where the drugs found to be most assayresistant (the most accurate predictions) are specifically excluded from use in patient treatment. Despite the fact that the design of the present study was, therefore, not optimum for determining the predictive accuracy of the DiSC Assay system in NSCLC (which would require all patients to be treated in a uniform fashion, irrespective of assay results), we were none-the-less able to demonstrate significant associations between in vitro drug resistance and response. Specimens from responding patients were, on the whole, significantly more sensitive to individual drugs, groups of drugs, and the drugs used in treatment than were specimens from non-responding patients. In vitro drug resistance differences between responding and non-responding patients were of greater significance than were differences between other laboratory and clinical measurements.
We found that the clearest correlations between clinical and in vitro drug resistance were obtained when the same drug(s) was(were) compared for all patients, regardless of the treatment they received. This finding is consistent with the theoretical considerations discussed earlier. Correlations were best in the case of etoposide (Tables V and VI, and Figures 1 and 2) and correlations were further improved by taking an average of several drugs, such as the average results for etoposide, doxorubicin, cisplatin, and vincristine. Some years ago, previous authors reported (using a different assay system) that the results of doxorubicin in vitro were highly predictive of the general clinical effectiveness of multiple different drugs (Groups for sensitivity testing of tumours (KSST), 1981) . This finding seemed somewhat improbable at the time, but recent work on the phenomenon of multidrug resistance provides a logical explanation to support the credibility of these earlier findings. Our own results are consistent with these observations. Our findings showed clear and significant associations between the general in vitro drug resistance to groups of drugs and the clinical response to multiple forms of three drug combination chemotherapy. We speculate that these associations might have been even more significant had patients all received uniform therapy with, for example, cisplatin-etoposide, but it will require further study to confirm or refute this speculation.
In other studies of drug resistance assays (Weisenthal, 1991; Weisenthal & Kern, 1991; Bosanquet, 1991) , results were cut at the median and at one standard deviation greater than (more resistant than) the median, identifying cohorts of patients with above-expected, below expected, and no chance of response. Results falling one or more standard deviations more resistant than the median were said to signify extreme drug resistance (EDR). In 50 assays successfully testing all 10 drugs performed on non-small cell lung cancer specimens (comprising assays for the present study and additional assays performed on specimens from other institutions), the median result for the average of all ten tested drugs was 59% cell survival and one standard deviation was 26%. Cutting assay results at the median and at one standard deviation greater than the median resulted in patient cohorts with response rates of 6/11 (55%), 3/9 (33%), and 0/5 (0%) for results less than the median, greater than the median to one standard deviation greater than the median, and greater than one standard deviation greater than the median, respectively. Although the numbers are small, these results offer further support for the concept of EDR as an objective phenomenon that can be identified as a cell culture assay result falling one standard deviation more resistant than the median of all assay results (ibid). It may be quite valuable to identify subsets of patients with very low response probabilities, to avoid the toxicity and expense of ineffective therapies, and, in turn, to identify patients who are better candidates for investigational trials than for 'standard' therapies with a very low likelihood of success. Another potentially useful application of such assays in NSCLC may be the selection of patients most likely to benefit from adjuvant chemotherapy to be administered along with surgery or radiation therapy (those patients with tumours not expressing EDR).
Recently, Gazdar and colleagues reported that a highly drug-resistant subset of small cell lung cancer patients was identified by the DiSC assay when this test was applied to early passage cell lines established from individual patients. Additionally, assay results were found to correlate both with response and with patient survival (Gazdar et al., 1990) . The DiSC assay has also been shown to correlate with response (Lathan et al., 1990; Tidefelt et al., 1989; Beksac et al., 1988; Kirkpatrick et al., 1990; Weisenthal et al., 1986; Bosanquet, 1991) and survival (Tidefelt et al., 1989; Bosanquet, 1991) in haematologic neoplasms. While the DiSC assay has previously been studied mainly in the case of haematologic neoplasms, other types of assay systems have been much more extensively studied in solid tumours (von Hoff et al., 1981; Scheithauer et al., 1988; Salmon, 1987; Hanauske et al., 1987; Hoff, 1986; Link et al., 1986; Sondak et al., 1985) . A recent analysis of a soft agar cell proliferation assay revealed that large numbers of drugresistant tumours could be identified in solid tumour patients with 99.2% specificity for the extreme drug resistance endpoint .
Conclusions
In conclusion, the results of the present study strongly suggest that the DiSC assay is clinically relevant for etoposide and probably for other drugs but possibly not for 5FU. These experimental observations are also consistent with some of the theoretical considerations discussed above. The data further suggest that assay results may be used to classify patients prior to treatment into distinct cohorts, having above average and below average probabilities of responding to chemotherapy (Figure 1 , Table V ). These preliminary data also suggest that the DiSC assay may be used to identify tumours with extreme drug resistance (EDR), using assay criteria similar to those previously proposed in other publications Bosanquet, 1991; Weisenthal, 1991; Weisenthal & Kern, 1991) . Although our series is small, results are sufficiently encouraging to support the initiation of further trials, including comparisons with other cell culture drug resistance assays and with other (non-cell culture) tests for drug resistance, such as P-glycoprotein (Merkel et al., 1988; Lai et al., 1989) and neuroendocrine markers (Graziano et al., 1989) .
